glp-1 and type 2 diabetes RA, GIP/GLP-1 RA – Trend Diabetes Dual GIP/GLP-1 receptor agonists: New

Throw it away immediately

Additionally, aspiration risk has been raised as a concern primarily in perioperative settings due to delayed gastric emptying, leading to recent multi-society anesthesia guidelines addressing GLP-1 receptor agonist management before procedures

By 2024, GLP-1 drugs had become blockbusters, with combined sales approaching $50 billion annually

GLP-1 receptor agonist therapy represents one of the most significant advances in medical weight loss and metabolic optimization, not because it's a quick fix, but because it works by addressing the underlying biological drivers of weight gain, appetite dysregulation, and cardiometabolic disease

Its main competitor, Eli Lilly and Company, is gearing up for an FDA decision on its own GLP-1 pill, orforglipron, sometime in the second quarter

Hunger cues may not be reliable while on this medication